home / stock / rhhvf / rhhvf quote
Last: | $235.30 |
---|---|
Change Percent: | -1.34% |
Open: | $239.172 |
Close: | $235.30 |
High: | $240.236 |
Low: | $234.2011 |
Volume: | 5,310 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$235.3 | $239.172 | $235.3 | $240.236 | $234.2011 | 5,310 | 05-02-2024 |
$236 | $246.078 | $236 | $246.078 | $235.81 | 3,898 | 05-01-2024 |
$238.8 | $240 | $238.8 | $243.382 | $235.8 | 2,994 | 04-30-2024 |
$240.12 | $240.12 | $240.12 | $244.336 | $240.12 | 2,267 | 04-29-2024 |
$242.36 | $236.986 | $242.36 | $246.53 | $235.8 | 369 | 04-26-2024 |
$237.716 | $236.73 | $237.716 | $241.738 | $235.8446 | 11,070 | 04-25-2024 |
$241.51 | $243.402 | $241.51 | $247.55 | $235.77 | 928 | 04-24-2024 |
$250.794 | $248.21 | $250.794 | $251.985 | $248.21 | 1,274 | 04-23-2024 |
$245.182 | $244 | $245.182 | $249.91 | $244 | 1,298 | 04-22-2024 |
$243.9799 | $237.09 | $243.9799 | $243.9799 | $237.09 | 5,153 | 04-19-2024 |
$240.062 | $236.98 | $240.062 | $243.8 | $236.98 | 1,675 | 04-18-2024 |
$242.62 | $240.358 | $242.62 | $242.936 | $238.05 | 3,474 | 04-17-2024 |
$243.5 | $238.85 | $243.5 | $243.696 | $238.85 | 3,681 | 04-16-2024 |
$244.48 | $248.01 | $244.48 | $248.01 | $243.378 | 403 | 04-15-2024 |
$244.912 | $246.582 | $244.912 | $248.8809 | $244.912 | 766 | 04-12-2024 |
$247.3 | $249 | $247.3 | $249.2 | $246.7 | 128,058 | 04-11-2024 |
$245.61 | $246.574 | $245.61 | $246.574 | $241.226 | 2,444 | 04-10-2024 |
$244.6 | $243.46 | $244.6 | $246.862 | $243.46 | 219,718 | 04-09-2024 |
$242.275 | $237.81 | $242.275 | $242.54 | $237.81 | 2,435 | 04-08-2024 |
$242.53 | $245 | $242.53 | $245.77 | $240.32 | 1,097 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Div Rts Company Name:
RHHVF Stock Symbol:
OTCMKTS Market:
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. The administrators signed a definitive ...
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted a...
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted a...